AMGN vs REGN Comparison: AI Score, Valuation, Performance and Upside
Compare Amgen and Regeneron by biosimilar exposure, GLP-1 obesity drug pipeline (MariTide), Dupixent vs Enbrel replacement, free cash flow, and which established biotech offers better risk-adjusted long-term returns.
Use this Amgen vs Regeneron comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
AMGN holds the edge across 3 of 5 key metrics in this comparison. AMGN has delivered stronger 1-year price return (+21.87% vs +16.18%), though REGN has the better forward P/E setup (12.36x vs 15.62x for AMGN). On fundamentals, REGN is growing revenue faster (19.00%), while AMGN maintains the higher operating margin (33.80%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for REGN (+21.06%) than for AMGN (-2.64%).
| Metric | AMGN | REGN |
|---|---|---|
| AI score | 47.8 | 42.6 |
| AI rank | #617 | #904 |
| Latest close | $376.04 | $656.01 |
| 1M return | +7.00% | +5.23% |
| 6M return | +9.08% | -12.94% |
| 1Y return | +21.87% | +16.18% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | AMGN | REGN |
|---|---|---|
| 1Y ago | $12.27K (+22.7%) started 2025-07-25 | $11.65K (+16.5%) started 2025-07-25 |
| 5Y ago | $19.97K (+99.7%) started 2021-07-26 | $11.4K (+14.0%) started 2021-07-26 |
| 10Y ago | $40.11K (+301.1%) started 2016-07-25 | $16.68K (+66.8%) started 2016-07-25 |
Hypothetical — past performance does not guarantee future results.
| Metric | AMGN | REGN |
|---|---|---|
| Market cap | $197.69B | $70.94B |
| Trailing P/E | 25.51 | 16.53 |
| Forward P/E | 15.62 | 12.36 |
| Price/Sales | 4.57 | 3.78 |
| EV/Revenue | 6.53 | 4.21 |
| Analyst target | $356.62 | $819.18 |
| Target upside | -2.64% | +21.06% |
| Metric | AMGN | REGN |
|---|---|---|
| Revenue growth | 5.80% | 19.00% |
| Earnings growth | 4.40% | -7.20% |
| EPS growth | +4.40% | -7.20% |
| FCF margin | +19.98% | +21.94% |
| Operating margin | 33.80% | 20.66% |
| Profit margin | 20.96% | 29.65% |
| ROIC proxy | 101.32% | 14.55% |
| Return on equity | 101.32% | 14.55% |
| Dividend yield | 2.75% | 0.56% |
| Beta | 0.40 | 0.24 |
| Debt/equity | 623.75 | 8.61 |
| Current ratio | 1.26 | 3.56 |
| Quick ratio | 0.85 | 2.84 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | AMGN | REGN |
|---|---|---|---|
| 1Y | Growth | +22.66% | +16.50% |
| CAGR | +22.73% | +16.55% | |
| Sharpe ratio | 0.73 | 0.50 | |
| Max drawdown | 16.57% | 26.05% | |
| Max daily drop | 5.14% | 9.82% | |
| Max wkly drop | 8.70% | 12.87% | |
| 5Y | Growth | +74.36% | +13.85% |
| CAGR | +11.77% | +2.63% | |
| Sharpe ratio | 0.40 | 0.09 | |
| Max drawdown | 24.86% | 59.69% | |
| Max daily drop | 7.14% | 19.01% | |
| Max wkly drop | 12.81% | 20.21% | |
| 10Y | Growth | +195.33% | +66.58% |
| CAGR | +11.44% | +5.24% | |
| Sharpe ratio | 0.38 | 0.18 | |
| Max drawdown | 24.86% | 59.69% | |
| Max daily drop | 9.58% | 19.01% | |
| Max wkly drop | 15.79% | 20.21% |
| Category | AMGN | REGN |
|---|---|---|
| Company | AMGN | REGN |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Biotechnology |
| Core business | N/A | N/A |
| Investor focus | N/A | N/A |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.